Fluvoxamine for the treatment of COVID-19. (2022)
Attributed to:
AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment
funded by
COVID
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s2214-109x(21)00592-1
PubMed Identifier: 35180411
Publication URI: http://europepmc.org/abstract/MED/35180411
Type: Journal Article/Review
Volume: 10
Parent Publication: The Lancet. Global health
Issue: 3
ISSN: 2214-109X